Guidance
Full-year sales guidance raised to 10-11%
Guidance · revenue to $6.75B
← Back to feed
01
02
03
04
Demand
Capex
EW
FY2026 Q2
RAISED
Edwards Lifesciences Corporation earnings call
Buzzberg read
Full-year sales guidance raised to 10-11%
Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%).
Buzzberg read Full-year sales guidance raised to 10-11% Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%). Read full analysisCollapse analysis
Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%).
- FY2026 total revenue guidance raised to 10-11% growth ($6.6-6.9B); TAVR to 8-9% ($4.75-5B); TMTT to $760-780M.
- Adjusted EPS guidance maintained at $2.95-$3.05 despite tax headwinds (higher effective rate).
- Q3 2026 guided to $1.63-1.71B revenue and $0.71-0.77 EPS, reflecting higher prior-year comps.
TAVR revenue
$1.3B
+8% QoQ
TMTT revenue
$0.1959B
+13% QoQ
Revenue
$1.741B
+6% QoQ
EPS
$0.78
+0% QoQ
What changed this quarter
Demand
TMTT revenue grew 44.8% year-over-year
Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.
Demand
TAVR global sales up 10.5% to $1.3B
TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.
Demand
Growth benefited from competitor exit in Q2 2025
TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.
Demand & capex
Bookings & conversion
TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.
Investment and capacity
Management stated that their highest capital allocation priority is investing in organic growth and strengthening the manufacturing network, with ongoing investment in the business supporting operating margin expansion.
Tone · confident
Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.
Forward guidance
RaisedGuidance · revenue to $6.75B
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $2.95–$3.05 | $3.00 | MAINTAINED |
| EPS | FY2026 Q3 | $0.71–$0.77 | $0.74 | GUIDED |
| Revenue | FY2026 | $6.6B–$6.9B | $6.75B | RAISED |
| RevenueTAVR | FY2026 | $4.75B–$5B | $4.875B | RAISED |
| RevenueTMTT | FY2026 | $0.76B–$0.78B | $0.77B | RAISED |
| Revenue | FY2026 Q3 | $1.63B–$1.71B | $1.67B | GUIDED |
Guidance credibility
6 / 6met or beat
| Issued | Metric | Target | Guide | Actual | Outcome |
|---|---|---|---|---|---|
| FY2026 Q1 | EPS | FY2026 Q2 | $0.70–$0.76 | $0.78 | Met / beat |
| FY2026 Q1 | Revenue | FY2026 Q2 | $1.66B–$1.74B | $1.741B | Met / beat |
| FY2025 Q4 | EPS | FY2026 Q1 | $0.70–$0.76 | $0.78 | Met / beat |
| FY2025 Q4 | Revenue | FY2026 Q1 | $1.55B–$1.63B | $1.6486B | Met / beat |
| FY2025 Q3 | EPS | FY2025 Q4 | $0.58–$0.64 | $0.58 | Met / beat |
| FY2025 Q3 | Revenue | FY2025 Q4 | $1.51B–$1.59B | $1.5696B | Met / beat |